ASP2453(5-30 mg/kg,口服,每日一次,持续 30 天)在小鼠异种移植模型(如 MIA PaCa-2 和 LXFA592)中表现出抗肿瘤活性。
参考文献:
1. Nakayama A, et al. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Br J Cancer. 2021 Nov 18.